$NBIX

Neurocrine Biosciences (NBIX) shares fell about 3.1% to $156.94 after three Prader-Willi patient groups issued a joint statement citing post-marketing safety data for Neurocrine’s Vykat XR, including seven patient deaths and 100+ serious adverse events reported to the FDA. The groups did not claim causality. CEO Kyle Gano disputed a link. Investors also weighed INGREZZA drug-pricing concerns; Q2 2026 revenue was reported above $950M.

Neurocrine Biosciences (NBIX) reported publication of Phase 4 KINECT-PRO data for INGREZZA in tardive dyskinesia. The once-daily capsules improved patient-reported quality of life and clinician-rated movement severity, with mean changes exceeding clinically meaningful thresholds at Week 24. About 58% achieved symptomatic remission. Results were published in CNS Spectrums.

Neurocrine Biosciences (NASDAQ:NBIX) shares fell 5.8% after Stat News reported patient deaths and severe side effects potentially linked to its Vykat drug for Prader-Willi syndrome. The report said 7 deaths and 100+ serious adverse events were recorded with the FDA as of July 31, though no definitive link was established. Neurocrine also published Phase 4 KINECT-PRO results for INGREZZA.

Neurocrine Biosciences (NASDAQ: NBIX) said published Phase 4 KINECT-PRO results for INGREZZA (valbenazine) showed once-daily treatment improved patient-reported quality of life and daily functioning in adults with tardive dyskinesia over 24 weeks. In an open-label study (n=59; 45 efficacy), mean TDIS change was -8.0 and AIMS -6.8, both exceeding MCID thresholds, and 58% met clinician-defined symptomatic remission at Week 24.

Neurocrine Biosciences shares fell 3.1% pre-open to $156.85, extending a corrective move. The decline follows three organizations raising safety concerns about Neurocrine’s Prader-Willi treatment Vykat XR, citing seven patient deaths and 100+ serious adverse event reports since March 2025 approval. FDA records list four deaths. No new catalysts; analysts had upgraded earlier.

Neurocrine Biosciences began a Phase I trial of NBIP-’1968, a long-acting triple agonist targeting GLP-1, GIP, and glucagon receptors, for obesity. The study will test tolerability and safety of single ascending doses in overweight or obese adults, aiming to support a once-weekly subcutaneous regimen. NBIP-’2118 is also in Phase I.

Simply Wall St says Neurocrine Biosciences (NBIX) reported Q2 2026 revenue of $959 million and net income of $144.4 million. It also filed a $742 million shelf registration for 4,000,000 common shares tied to an ESOP offering. The piece links stronger profitability and potential dilution to investor expectations around INGREZZA and CRENESSITY.

Neurocrine Biosciences (NBIX) said it has started a Phase 1 first-in-human clinical study of NBIP-’1968 to assess safety and tolerability. The company described the program as part of its obesity and metabolic disease pipeline.

Neurocrine Biosciences (Nasdaq: NBIX) said it has started a Phase 1 first-in-human study of NBIP-'1968, an investigational GLP-1/GIP/glucagon triple agonist for obesity. The trial will assess single ascending doses for safety and tolerability in adults across BMI categories, with once-weekly subcutaneous dosing. NBIP-'1968 is planned as a fixed-dose combination with NBIP-'2118.

Neurocrine Biosciences reported Q2 2026 results and discussed its shift to a diversified portfolio. Management said INGREZZA record new patient additions supported raised full-year guidance midpoint for 13% YoY growth. CRENESSITY launch progress and Soleno and VYKAT XR acquisitions were highlighted. Soleno was $2.9B cash-funded; quarter-end cash was $500M and no debt.